NCT06963281
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06963281
Title Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.